Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohamed A Kamal

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Infectious Disorders Drug Targets|May 17, 2013
Oseltamivir pharmacology in young children: a commentaryMohamed A Kamal
Journal of Clinical Pharmacology|August 20, 2004
Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assaysMohamed A Kamal, William J Jusko
Drug Metabolism and Pharmacokinetics|September 3, 2008
Role and relevance of PEPT2 in drug disposition, dynamics, and toxicityMohamed A Kamal, Richard F Keep, David E Smith
Clinical Pharmacology and Therapeutics|July 16, 2024
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory ApprovalMohamed A Kamal, Samit Ganguly, Ananth Kadambi, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|February 20, 2009
Influence of genetic knockout of Pept2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 null miceMohamed A Kamal, Huidi Jiang, Yongjun Hu, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 5, 2015
Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studiesFlor M Muñoz, Evan J Anderson, Jaime G Deville, et al.
Clinical and Translational Science|July 31, 2024
Dupilumab: Mechanism of action, clinical, and translational scienceMarc R McCann, Matthew P Kosloski, Christine Xu, et al.
Journal of Pharmaceutical Sciences|March 10, 2010
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureMohamed A Kamal, David E Smith, Jack Cook, et al.
Clinical and Translational Gastroenterology|January 24, 2025
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
Clinical and Translational Gastroenterology|December 2, 2024
Symptomatic Improvement in Adults and Adolescents with Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Infectious Disorders Drug Targets|May 17, 2013
Oseltamivir pharmacology in young children: a commentaryMohamed A Kamal
Journal of Clinical Pharmacology|August 20, 2004
Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assaysMohamed A Kamal, William J Jusko
Drug Metabolism and Pharmacokinetics|September 3, 2008
Role and relevance of PEPT2 in drug disposition, dynamics, and toxicityMohamed A Kamal, Richard F Keep, David E Smith
Clinical Pharmacology and Therapeutics|July 16, 2024
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory ApprovalMohamed A Kamal, Samit Ganguly, Ananth Kadambi, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|February 20, 2009
Influence of genetic knockout of Pept2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 null miceMohamed A Kamal, Huidi Jiang, Yongjun Hu, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 5, 2015
Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studiesFlor M Muñoz, Evan J Anderson, Jaime G Deville, et al.
Clinical and Translational Science|July 31, 2024
Dupilumab: Mechanism of action, clinical, and translational scienceMarc R McCann, Matthew P Kosloski, Christine Xu, et al.
Journal of Pharmaceutical Sciences|March 10, 2010
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureMohamed A Kamal, David E Smith, Jack Cook, et al.
Clinical and Translational Gastroenterology|January 24, 2025
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
Clinical and Translational Gastroenterology|December 2, 2024
Symptomatic Improvement in Adults and Adolescents with Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
Pageof 6